Curis to Present at UBS Global Pharmaceuticals Conference
Tuesday May 17, 8:30 am ET
CAMBRIDGE, Mass.--(BUSINESS WIRE)--May 17, 2005--Curis, Inc. (NASDAQ: CRIS - News), a therapeutic drug development company, today announced that the Company will be presenting at the UBS Global Pharmaceuticals Conference on Tuesday, May 24, at the Grand Hyatt New York Hotel in New York City.
Daniel Passeri, Curis' President and Chief Executive Officer, will provide an overview of the status of Curis' business and collaborations at 7:30 a.m. EDT. There will be an audio webcast of the presentation at: event.streamx.us
The presentation will be archived approximately three hours after the live event and available for 30 days following the conference. The presentation will also be available on the Investor Relations section of Curis' website at www.curis.com.
About Curis, Inc.
Curis, Inc. is a therapeutic drug development company. The Company's technology focus is on regulatory pathways that control repair and regeneration. Curis' product development involves the use of proteins or small molecules to modulate these pathways. Curis has successfully used this technology and product development approach to produce several promising drug product candidates in the fields of cancer (under collaboration with Genentech, which also includes a co-development arrangement for a basal cell carcinoma product candidate), kidney disease (licensed to Ortho Biotech Products, a subsidiary of Johnson & Johnson), neurological disorders (under collaboration with Wyeth), hair growth, and cardiovascular disease. For more information, please visit the Curis web site at www.curis.com. |
